# OnCo record response (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/response/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "response", "NCT01243944" ;
  schema:name "RESPONSE"@en ;
  schema:description "RESPONSE showed that ruxolitinib controls the haematocrit and shrinks the spleen in PV patients hydroxyurea has failed, and won the first drug approval specific to that setting."@en ;
  schema:url <https://onco.cc/trials/response/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01243944>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1409002> ;
  onco:status "positive" ;
  onco:tag "polycythaemia-vera", "mpn" ;
  onco:phase "3" ;
  schema:startDate "2010-10-27" ;
  onco:cancers <https://onco.cc/cancers/polycythaemia-vera/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/pipobroman/> ;
  onco:companies <https://onco.cc/companies/incyte/>, <https://onco.cc/companies/novartis/> .